The biologic spectrum of thymic epithelial neoplasms: Current status and future prospects

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 8, Issue 11, 2010, Pages 1322-1328

  Cheney, Richard T ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

EGFR; Kit (CD117); Masaoka stage; Mediastinal neoplasms; Targeted therapy; Thymic carcinoma; Thymoma; Who classification

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; PROTEIN P21; PROTEIN P27; PROTEIN P53; STEM CELL FACTOR RECEPTOR;

CANCER CLASSIFICATION; CANCER STAGING; CARCINOGENESIS; CLINICAL FEATURE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; ORGANOGENESIS; REVIEW; THYMOMA; THYMUS CANCER; TUMOR GROWTH;

EID: 78951488368     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2010.0097     Document Type: Review

References (66)

1. Rosai J, ed. Rosai and Ackerman's Surgical Pathology, 9th ed. Philadelphia, PA: Mosby; 2004:459-513.
2. Giaconne G. Treatment of malignant thymoma. Curr Opin Oncol 2005;17:140-146.
3. Rajan A, Giaccone G. Treatment of advanced thymoma and thymic carcinoma. Curr Treat Options Oncol 2008;9:277-287.
4. Falksoon CB, Bezjak A, Darling G, et al. The management of thymoma: a systematic review and practice guideline. J Thorac Oncol 2009;4:911-919.
5. Muller-Hermelink HK, Engel P, Kuo TT, et al. Tumors of the thymus. In: Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, eds. World Health Classification of Tumours, Pathology & Genetics: Tumors of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; 2004:146-248.
6. Margaritora S, Cesario A, Cusumano G, et al. Thirty-five year follow-up analysis of clinical and pathologic outcomes of thymoma surgery. Ann Thorac Surg 2010;89:245-252.
7. Pan CC, Chen PC, Wang, LS, et al. Thymoma is associated with an increased risk of second malignancy. Cancer 2001;92:2406-2411.
8. Evoli A, Punzi C, Marsili F, et al. Extrathymic malignancies in patients with thymoma. Ann Oncol 2004;15:692-693.
9. Ecco R, Langohr IM, Tury E, et al. Mixed thymoma in a cow. J Vet Diagn Invest 2006;18:503-507.
10. Akiyama T, Morita T, Takimoto Y, Shimada A. Lymphoepithelial thymoma characterized by proliferation of spindle cells in a Samoyed dog. J Vet Med Sci 2009;71:1265-1267.
11. Suster S, Rosai J. Thymus. In: Mills SE, ed. Histology for Pathologists, 3rd ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 2007:505-525.
12. Res P, Spits H. Developmental stages in the human thymus. Semin Immunol 1999;11:39-46.
13. Datta MW, Shahsafaei A, Nadler LM, et al. Expression of MHC class II- associated invariant chain (Ii;CD74) in thymic epithelial neoplasms. Appl Immunohistochem Mol Morphol 2000;8:210-215.
14. Gill J, Malin M, Hollander GA, Boyd R. Generation of a complete thymic microenvironment by MTS24+ thymic epithelial cells. Nat Immunol 2002;3:635-640.
15. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stage. Cancer 1981;48:2485-2492.
16. Bergh NP, Gatzinsky P, Larsson S, et al. Tumors of the thymus and thymic region. I. Clinicopathological studies on thymomas. Ann Thorac Surg 1978;25:91-98.
17. Wilkins EW, Castleman B. Thymoma: a continuing survey at the Massachusetts General Hospital. Ann Thorac Surg 1979;28:252-256.
18. Chen G, Marx A, Wen-Hu C, et al. New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China. Cancer 2000;95:420-429.
19. Blumberg D, Burt ME, Bains MS, et al. Thymic carcinoma: current staging does not predict prognosis. J Thorac Cardiovasc Surg 1998;115:303-309.
20. Wright CD, Wain JC, Wong DR, et al. Predictors of recurrence in thymic tumors: importance of invasion, World Health Organization histology, and size. J Thorac Cardiovasc Surg 2005;130:1413-1421.
21. Ettinger DS, Akerley W, Bepler G, et al. NCCN clinical practice guidelines in oncology: thymic malignancies. version 2, 2010. Available at: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp. Accessed September 27, 2010.
22. Edge SB, Byrd DR, Compton CC, et al, eds. AJCC Cancer Staging Manual, 7th ed. New York: Springer; 2010.
23. Bernatz PE, Harrison EG, Clagett OT. Thymoma: a clinicopathologic study. J Thoracic Cardiovasc Surg 1961;42:424-444.
24. Kirchner T, Muller-Hermelink HK. New approaches to the diagnosis of thymic epithelial tumors. Prog Surg Path 1989;10:167-189.
25. Muller-Hermelink HK, Marx A. Pathologic aspects of malignant and benign thymic disorders. Ann Med 1999;31(Suppl 2):5-14.
26. Suster S, Moran CA. Thymoma, atypical thymoma, and thymic carcinoma. Am J Clin Path 1999;111:826-833.
27. Suster S, Moran CA. Primary thymic epithelial neoplasms: spectrum of differentiation and histologic features. Semin Diagn Pathol 1999;16:2-17.
28. Levine GD, Rosai J. Thymic hyperplasia and neoplasia: a review of current concepts. Human Pathol 1978;9:495-515.
29. Suster S, Rosai J. Thymic carcinoma: a clinicopathologic study of 60 cases. Cancer 1991;67:1025-1032.
30. Suster S, Moran CA. Thymic carcinoma: spectrum of differentiation and histologic types. Pathology 1998;30:111-122.
31. Takahashi F, Tsuta K, Matsuno Y, et al. Adenocarcinoma of the thymus: mucinous subtype. Human Pathol 2005;36:219-223.
32. Choi WWL, Lui YH, Lau WH, et al. Adenocarcinoma of the thymus. Am J Surg Pathol 2003;27:124-130.
33. Ra SH, Fishbein MC, Baruch-Oren T, et al. Mucinous adenocarcinomas of the thymus: a report of 2 cases and review of the literature. Am J Surg Pathol 2007;31:1330-1336.
34. Suster S, Moran CA. Spindle cell thymic carcinoma: clinicopathologic and immunohistochemical study of distinctive variant of primary thymic epithelial neoplasm. Am J Surg Pathol 1999;23:691-700.
35. Okudela K, Nakamura N, Sano JY, et al. Thymic carcinosarcoma consisting of squamous cell carcinomatous and embryonal rhabdomyosarcomatous components. Pathol Res Pract 2001;197:205-210.
36. Eimoto T, Kitaoka M, Ogawa H, et al. Thymic sarcomatoid carcinoma with skeletal muscle differentiation: report of two cases, one with cytogenetic analysis. Histopathol 2002;40:46-57.
37. Brown JG, Familiari U, Papotti M. Rosai J. Thymic basaloid carcinoma: a clinicopathologic study of 12 cases, with a general discussion of basaloid carcinoma and its relationship with adenoid cystic carcinoma. Am J Surg Pathol 2009;33:1113-1124.
38. Suster S, Moran CA. Primary thymic epithelial neoplasm showing combined features of thymoma and thymic carcinoma: a clinicopathologic study of 22 cases. Am J Surg Pathol 1996;20:1469-1480.
39. Strobel P, Bauer A, Puppe B, et al. Tumor recurrence and survival in patients treated for thymoma and thymic squamous cell carcinomas: a retrospective analysis. J Clin Oncol 2004;22:1501-1509.
40. Okumura M, Miyoshi S, Fujii Y, et al. Clinical and functional significance of WHO classification on human thymic epithelial neoplasms: a study of 146 consecutive cases. Am J Surg Pathol 2001;25:103-110.
41. Rieker RJ, Hoegel J, Morresi-Hauf A, et al. Histologic classification of thymic epithelial tumors: comparison of established classification schemes. Int J Cancer 2002;98:900-906.
42. Rena O, Papalia E, Maggi G, et al. World Health Organization histologic classification: an independent prognostic factor in resected thymomas. Lung Cancer 2005;50:59-66.
43. Kim DJ, Yang IW, Choi SS, et al. Prognostic and clinical relevance of the world health organization schema for the classification of thymic epithelial tumors: a clinicopathologic study of 108 patients and literature review. Chest 2005;127:755-761.
44. Lee HS, Kim ST, Lee J, et al. A single institutional experience of thymic epithelial tumors over 11 years: clinical features and outcome and implications for future management. Br J Cancer 2007;97:22-28.
45. De Jong WK, Blaauwgeers JL, Schaapveld M, et al. Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy. Eur J Cancer 2008;44:123-130.
46. Hosaka Y, Tsuchida M, Toyabe SI, et al. Masaoka stage and histologic grade predict prognosis in patients with thymic carcinoma. Ann Thorac Surg 2010;89:912-917.
47. Wilkins KB, Sheikh E, Green R, et al. Clinical and pathologic predictors of survival in patients with thymoma. Ann Surg 1999;230:562-574.
48. Okulmura M, Ohta M, Tateyama H, et al. The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer 2002;94:624-632.
49. Nakagawa K, Asamura H, Matsuno Y, et al. Thymoma: a clinicopathologic study based on the new World Health Organization classification. J Thorac Cardiovasc Surg 2003;126:1134-1140.
50. Detterbeck FC. Clinical value of the WHO classification system of thymoma. Ann Thorac Surg 2006;81:2328-2334.
51. Ionue M, Marx A, Zettl A, et al. Chromosome 6 suffers frequent and multiple aberrations in thymoma. Am J Pathol 2002;161:1507-1513.
52. Pan CC, Chen PC, Chiang H. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymoma. J Pathol 2004;202:375-381.
53. Tsuchida M, Umezu H, Hashimoto T, et al. Absence of gene mutations in KIT-positive thymic epithelial tumors. Lung Cancer 2008;62:321-325.
54. Henley JD, Cummings OW, Loehrer PJ. Tyrosine kinase receptor expression in thymomas. J Cancer Res Clin Oncol 2004;130:222-224.
55. Strobel P, Hartmann M, Jakob A, et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med 2004;350:2625-2626.
56. Meister M, Schirmacher P, Dienemann H, et al. Mutational status of epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinoma. Cancer Lett 2007;248:186-191.
57. Suzuki E, Sasaki H, Kawano O, et al. Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors. Jpn J Clin Oncol 2006;36:351-356.
58. Ionescu DN, Sasatomi E, Cieply K, et al. Protein expression and gene amplification of epidermal growth factor receptor in thymomas. Cancer 2005;103:630-636.
59. Baldi A, Amgrogi V, Mineo D, et al. Analysis of cell cycle regulator proteins in encapsulate thymomas. Clin Can Res 2005;11:5078-5083.
60. Zisis C, Rontogianni D, Stefanaki K, Bellenis I. Expression of cyclins D1, D3, and p27 in thymic epithelial tumors. Interact Cardiovasc Thorac Surg 2004;3:245-248.
61. Hiroshima K, Iyoda A, Toyozaki T, et al. Proliferative activity and apoptosis in thymic epithelial neoplasms. Mod Pathol 2002;15:1326-1232.
62. Inoue M, Starostik P, Zettl A, et al. Correlating genetic aberrations with World Health Organization-defined histology and stage across the spectrum of thymomas. Cancer Res 2003;63:3708-3715.
63. Zettl A, Strobel P, Wagner K, et al. Recurrent genetic aberrations in thymoma and thymic carcinoma. Am J Pathol 2000;157:257-266.
64. Penzel R, Hoegel J, Schmitz W, et al. Clusters of chromosomal imbalances in thymic epithelial tumours are associated with the WHO classification and the staging system according to Masaoka. Int J Cancer 2003;105:494-498.
65. Lee GY, Yang WI, Jeung HC, et al. Genome-wide genetic aberrations of thymoma using cDNA microarray based comparative genomic hybridization. BMC Genomics 2007;8:305-320.
66. Marx A, Strobel P. Update on thymoma pathology. Lessons from molecular and translational studies. Ann Pathol 2009;29(Spec No 1):S22-24.